Carmat (PAR: ALCAR)

Last close As at 23/05/2024


−0.08 (−0.92%)

Market capitalisation


Carmat is developing a biocompatible, artificial heart to satisfy the lack of donor hearts available for terminal heart failure patients. The development process combines the expertise of a wide range of technical and medical experts.

Latest Insights

View More

Healthcare | edison tv

Carmat: Edison Open House Healthcare 2022

Healthcare | Update

Carmat — Implantation momentum

Healthcare | edison tv

Carmat – Edison Open House interview

Healthcare | edison tv

Carmat – executive interview with Stéphane Piat

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (2.4) (21.8) (17.4)
Relative (7.4) (25.3) (27.4)
52 week high/low €14.8/€8.0


Edison Investment Research is terminating coverage on Carmat (ALCAR). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2020A 0.0 N/A (38.7) (285.32) N/A N/A
2021A 2.2 N/A (61.9) (402.00) N/A N/A
2022E N/A N/A N/A N/A N/A N/A
2023E N/A N/A N/A N/A N/A N/A



Carmat — Update 15 July 2016



Carmat — Update 5 May 2016